Nemes Rush Group’s SELLAS Life Sciences SLS Stock Holding History

Nemes Rush Group’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$148K	Hold	10,000	–	–	0.01%	248
2026 Q1	$42.3K	Hold	10,000	–	–	﹤0.01%	381
2025 Q4	$37.7K	Hold	10,000	–	–	﹤0.01%	377
2025 Q3	$16.1K	Hold	10,000	–	–	﹤0.01%	442
2025 Q2	$21.9K	Hold	10,000	–	–	﹤0.01%	411
2025 Q1	$10.8K	Hold	10,000	–	–	﹤0.01%	459
2024 Q4	$10.4K	Hold	10,000	–	–	﹤0.01%	460
2024 Q3	$10.1K	Hold	10,000	–	–	﹤0.01%	400
2024 Q2	$11.9K	Hold	10,000	–	–	﹤0.01%	392
2024 Q1	$10.1K	Hold	10,000	–	–	﹤0.01%	435
2023 Q4	$10.6K	Hold	10,000	–	–	﹤0.01%	421
2023 Q3	$16.4K	Hold	10,000	–	–	﹤0.01%	356
2023 Q2	$15.7K	Buy	+10,000	New	+$16.1K	﹤0.01%	382

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Nemes Rush Group's SLS Position: Q2 2026 in Review

Nemes Rush Group held its SELLAS Life Sciences (SLS) position steady in Q2 2026 at 10,000 shares worth $148K. The position accounts for 0.01% of the portfolio, ranked #248.

Nemes Rush Group first reported a position in SLS in Q2 2023 and has held it in 13 quarters since. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

Nemes Rush Group held 10,000 shares of SELLAS Life Sciences worth $148K as of Q2 2026.
Nemes Rush Group left its SELLAS Life Sciences share count unchanged in Q2 2026.
SELLAS Life Sciences made up 0.01% of Nemes Rush Group's portfolio in Q2 2026, its #248 holding.
Nemes Rush Group first reported a position in SELLAS Life Sciences in Q2 2023 and has held it in 13 quarters since.
193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.